Case presentation
A 66-year-old man was admitted to the intensive care unit (ICU) with respiratory failure after an episode of vomiting and aspiration of gastric contents. He was generally in good health, but had a recent history of excess social alcohol consumption over a period of two years. He rapidly developed acute respiratory distress syndrome (ARDS) and required intravascular volume loading and noradrenaline support for shock.
His condition stabilised and after emerging from alcohol withdrawal and sedation at day 5 in the ICU, weaning from mechanical ventilation was attempted. He still required a fractional inspired oxygen (FiO 2 ) of 0.40 and positive endexpiratory pressure (PEEP) of 8 cm H 2 O to maintain an arterial oxygen tension (PaO 2 ) of 10.8 kPa with a PaO 2 /FiO 2 ratio of 27, consistent with ARDS; his oxygen saturation fell rapidly when PEEP was reduced.
Ultrasound of the chest demonstrated bilateral basal consolidation, small (non-drainable) pleural effusions and bilateral lung 'comets' in the non-dependent lung consistent with interstitial syndrome, or thickening of the interlobular septae to a degree equivalent to ground glass appearances on computerised tomography. 1 He had a cumulative fluid balance +15.0 L from ICU admission and, as he no longer required vasoactive support and had otherwise normal biochemical renal function the decision was made to attempt to achieve negative fluid balance. 2 The drug regime used and physiological rationale are considered in detail later in this article. Tables 1 and 2 illustrate his blood, fluid balance and urinary changes over the next 72 hours.
After 72 hours of treatment, with FiO 2 of 0.4 and a PEEP of 5 cm H 2 O, his PaO 2 was 13.2 kPa (PaO 2 /FiO 2 of 33.0, consistent with acute lung injury (ALI) rather than ARDS). He was neurologically appropriate and his trachea was extubated uneventfully. He required supplementary nasal oxygen at 2 L/min and the strategy of aiming for negative fluid balance ceased. The patient mobilised approximately 10 L of fluid via the urine output within 72 hours, with almost no effect on the major components of blood biochemistry.
Mobilising oedema in the oedematous critically ill patient with ARDS: do we seek natriuresis not diuresis?
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In the treatment of the acute respiratory distress syndrome in the intensive care unit, one of the aims is to achieve a negative fluid balance. Traditional use of sole-agent loop diuretics such as furosemide often results in the loss of free water, dehydration, hypernatraemia and metabolic alkalosis, with therapeutic failure once water is replaced. A more rational approach is to induce natriuresis with loss of sodium in the urine to reduce extracellular and interstitial fluid volume, not total body water. Polypharmacy with a loop diuretic combined with other weak diuretics to prevent tubules modifying glomerular filtrate, promotes natriuresis with large volume urinary losses and minimal electrolyte disturbance, and the excretion of urine with a composition comparable to plasma. 
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Discussion
Oedema, a (pathological) accumulation of interstitial fluid, is a common condition in the critically ill, and its presence contributes to the development of ARDS. In the critically ill, oedema is an independent adverse prognostic factor and in this population typically reflects pan-endothelial dysfunction. Systemic insults and secondary inflammation induce vascular changes, eg the development of capillary pores, the loss of tight junction integrity and perhaps most importantly, loss of basement membrane negative charge. This alteration of the acellular basement membrane matrix results in the loss of mutual repulsion of anionic proteins, most importantly albumin, with resultant 'leakiness.' There are often associated insults impairing lymphatic clearance and promoting venous pooling, eg positive pressure ventilation and PEEP. The reduced vascular reflection coefficient and 'leakiness' may manifest as tissue oedema, normal left atrial pressure (non-hydrostatic) pulmonary oedema (ARDS), microalbuminuria or body cavity effusions, constituting the 'capillary leak syndrome.' [3] [4] [5] [6] [7] [8] While the concepts behind Starling' s forces and fluid movements at the capillary and microvascular level are included in most standard texts (Figure 1 ), the individual parameters involved cannot be measured at the bedside and their contribution to pathophysiology in individual patients is difficult to discern. Soni compared oedema to the black box of a crashed aircraft, which cannot be opened; its existence clearly signifies a catastrophe has occurred, but the details remain obscure. 9 While the role of inflammation and capillary leak has perhaps been under-recognised outside ICU, eg in acute coronary syndrome or heart failure, it is rarely as extreme as within ICU, and 'non-ICU oedema' is associated with conditions of abnormal sodium (Na + ) and extracellular fluid (ECF) homeostasis. Outside the ICU, most oedema is seen on renal, cardiac and liver units and reflects deranged sodium homeostasis.
The total body sodium (TB Na + ) content is essentially distributed throughout the extracellular fluid compartment (ECF) with only approximately 3% intracellular, in contrast to potassium. The serum sodium concentration (Na + ) may thus be derived if one knows the ECF volume.
[Na + ]= TB Na + /ECF The typical [Na + ] is 140 mmol/L and there are 15.0 L extracellular fluid in an average 70 kg male, making the TB Na + approximately 2,100 mmol. The urine output in the patient presented above, based upon recorded volume and electrolyte composition, eliminated over 1,500 mmol of sodium, almost equivalent to three quarters of the original total body sodium. Certainly the source of much of this sodium was iatrogenic resuscitation fluid; indeed with administration of 15.0 L of 'isotonic fluid' with [Na + ] 150 mmol/L, this patient had accumulated approximately 750 mmol at extubation . Even with the use of colloid suspensions, and even with the advent of 'balanced' solutions with a reduced chloride component, the concentration of sodium of almost all resuscitation fluids remains nearer to 150 than physiologic 140 mmol/L.
If the typical urine output is 1.0-1.5 mL/kg/h in health, this represents a tiny fraction of the 1.5 mL/kg/min of glomerular 524  173  36  116  2,197   72 hours  463  143  40  118  2,415   Table 2 Urine results during negative fluid balance strategy. Key: dQ/dt = rate of interstitial ('tissue') fluid formation, Pa = proximal arteriolar hydrostatic pressure, Pv = distal venular hydrostatic pressure, Oi = interstitial fluid oncotic pressure, Oc = capillary contents oncotic pressure, Kf = filtration constant capillary bed, σ = capillary reflection coefficient (Within the lungs the hydrostatic gradient, in health, is more accurately described by the difference between pulmonary arterial and transalveolar pressure, West zone 2).
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In health σ is 0.8-0.9 and hence capillary integrity ensures function as a semi-permeable membrane. In conditions of generalised oedema of a renal, hepatic or cardiac origin, the main problem is total body sodium overload and capillary integrity is generally maintained. Hence, in the setting of acute myocardial infarction for instance, a pulmonary capillary wedge pressure (PCWP) of 18 mm Hg or more is required to form hydrostatic pulmonary oedema.
However, in most critical illness pan-endothelial dysfunction exists which may be manifest variously as tissue oedema, ARDS/ALI, microalbuminuria. The value of σ falls substantially, on occasions nearing 0.1-0.2, the formation of tissue fluid becomes dependent upon the hydrostatic gradients. Hence for a patient with, for example, sepsis and a low reflection coefficient, a PCWP of 'normal' values, 8-12 mm Hg, may be sufficient to form hydrostatic pulmonary oedema, even though left atrial pressures are not regarded as elevated by traditional values. As attractive as this model is, few of the parameters within it can be measured at the bedside and hence its ability to predict a clinical consequence, eg oedema is limited. 10 filtrate (under 2%), and when the patient is suffering from shock will physiologically become considerably less. Without tubular modification, largely salt and secondary water absorption, the urine output through direct glomerular filtration would be in excess of 7.0 L/h and death would rapidly result. The kidneys have evolved to ensure oliguria and salt retention and to modify this innate property, ie to induce natriuresis, requires active intervention by the clinician.
There is a perennial debate regarding initial optimal fluid management in patients at risk of developing ARDS, and balancing the risk of increased tissue oedema during fluid resuscitation, with the risk of decreased vital organ perfusion and a lower intravascular pressure with less fluid, remains difficult. 2, 10 Equally valid and unresolved arguments are whether excess fluid promotes pulmonary oedema or whether adequate volume loading can avert the inflammatory process which 'drives' ARDS. Further, the lung can be the source of systemic inflammation, and thus could injure 'itself' in ARDS, rather than being secondarily injured by inflammation. [3] [4] [5] While the initial fluid management of patients at risk of ARDS is controversial, the subsequent management once ARDS is established, in the absence of haemodynamic compromise, is clearer. The FACCT study demonstrated improved outcomes in ARDS with negative fluid balance. 2 Furthermore, the study design of FACCT required a delay of 12 hours after shock had resolved prior to diuresis. Excess fluid states are associated with adverse outcomes in ARDS. 11, 12 It is therefore common ICU practice to attempt to achieve negative fluid balance, where possible, in patients with haemodynamically stable ARDS and where renal function is preserved; this is typically accomplished by diuresis (ie increasing water elimination) in patients.
In attempting to improve ARDS, the intention is to reduce the extracellular fluid compartment volume, and thus pulmonary interstitial oedema, and thereby to improve pulmonary mechanics and oxygenation; more specifically, reducing (pulmonary) interstitial fluid volume while maintaining the circulating volume (also part of the ECF) and intracellular volume. In order to safely and effectively remove pulmonary fluid via the kidneys then, certain pre-conditions should be met: • The patient should be haemodynamically stable. This is difficult to define, but it is unusual for patients to tolerate fluid shifts while requiring vasoactive support. Hence, negative fluid balance is typically associated with longer-stay patients who no longer require vasoactive agents and who have developed a positive fluid balance • The normal mechanisms of fluid homeostasis must be partially restored and a degree of vascular integrity returned. This, similarly, is a qualitative judgement and difficult to define quantitatively. Subsequent to the actions of Na + /K + -ATPase, sodium, the predominant extracellular cation, provides the main determinant for the ECF osmotic control. For example, one could describe hypovolaemic shock as TB Na + deficit, correction of which with resuscitation fluids restores the TB Na + ; it is no coincidence that most fluid resuscitation is with crystalloid (or colloid suspended in crystalloid) of an isotonic (although hypernatraemic) nature. Congestive cardiac renal or liver failure are TB Na + -excess conditions, despite often being associated with low serum sodium concentration. By comparison, in the syndrome of inappropriate antidiuretic hormone secretion (SIADH) there is often an excess total body water volume of several litres, yet oedema is rare as this is not accompanied by a TB Na + increase. The accumulated water load of SIADH is distributed throughout the total body water (approximately 45 L) rather than the smaller extracellular compartment. Most oedematous conditions reflect a disorder of Na + not water; water follows Na + to the ECF and interstitium, not the reverse. Hence, in managing oedematous conditions most clinicians incorrectly seek a diuresis (ie loss of water in urine) whereas they require a natriuresis (loss of sodium in urine). For example, the FACTT trial suggested single agent diuresis with furosemide. 2, 10 In achieving mobilisation of (lung) fluid via the kidneys, a degree of return of normal fluid dynamics and handling by the patient and restoration of a significant component of the reflection coefficient is necessary. Ultimately the body must be able to mobilise interstitial fluid to the vascular compartment to be filtered at the glomerulus if this is to be effective, underlying the requirement for the return of a level of normal fluid dynamics. The precise mechanisms involved in this homeostasis have received relatively little research attention and are currently far from clear. Indeed, the mechanisms of intracellular volume maintenance and osmotic control are poorly understood and worthy of more research. Snapshots suggest roles for intracellular osmoles, such as glutamine and taurine, and middle molecules (so called idiogenic osmoles), but this has been a relatively neglected area for research. 13 Data in relatively well perioperative patients suggest that administered sodium loads can take a surprisingly long time to be mobilised, in some cases up to a week, and the factors associated with endogenous mobilisation of (sodium-rich) fluid loads are poorly understood. 14 As important as the volume of fluid eliminated, is the composition of that fluid. It is relatively easy to obtain a 'diuresis' and renal clearance of free water, but almost complete sodium retention is a fundamental function of the kidney and natriuresis is therefore more difficult to achieve. Most clinicians use furosemide to offload patients and mobilise fluid. 2 The use of furosemide in this patient established a fairly typical sequence of events: 1. Furosemide was given to the patient with good diuresis and net negative fluid balance. 2. Over 24-48 hours, hypernatraemia and azotaemia developed (secondary to dehydration) with metabolic alkalosis. 3. Concerns over dehydration (eg confusion) prompted readministration of free water to correct the deficit. 4. While having induced significant osmotic shifts for the patient, at the end of five days, the TB Na + and fluid balance remained almost unaltered. Significant negative balance with furosemide came at the expense of profound dehydration. While furosemide is potent, relatively devoid of adverse effects, available as an intravenous agent and familiar to clinicians, its mode of action does not promote natriuresis. In blocking the 2Cl -/Na + -K + transporter of the ascending limb of the loop of Henle, the countercurrent mechanism of the medullary concentrating gradient is antagonised and consequently the maximal urinary concentration (up to 1,300 mOsm/kg in health) is reduced ie furosemide promotes diuresis not natriuresis.
Despite dehydration with furosemide, the rise in urea is often disproportionately small. The clearance of urea, because it is a small and mobile molecule and cannot be concentrated well, reflects total urine volume passed. In many polyuric states, eg recovery from oliguric renal failure, there is often a disproportionately small rise in plasma urea concentration.
In mobilising oedema fluid in ARDS, the goals of therapy are: 1. To increase total urine output and achieve a negative fluid status. However, to maintain haemodynamic stability it is important that the rate of urinary excretion does not exceed the rate of intracellular and extracellular fluid mobilisation to the vascular compartment. Data on mobilising tissue fluid are sparse and typically derived from chronic (intermittent) dialysis patients. 15 We therefore targeted a maximal mobilisation and urine output of 400 mL/h, equating to a 'typical' 1,500 mL ultrafiltrate removal over four hours of intermittent haemodialysis. 2. To promote natriuresis and urine composition identical to plasma and thus reduce TB Na + . 3. To avoid typical electrolyte derangements seen with diuretics, ie dehydration, hypernatraemia and alkalosis. Polypharmacy and refinement of the use of loop diuretics does allow tubular modifications of the composition of the intra-nephron glomerular filtrate. Many agents exert only weak effects in increasing urine volume, and are thus regarded as weak diuretics, yet have significant effects on urine composition. To achieve these aims we administered the following combination, detailed in Table 3 .
This combination of agents exerts actions along most of the length of the nephron (Figure 2) .
The intention is to ensure that the glomerular filtration rate (GFR) is maintained, tubular modification is largely abolished, and a filtrate with comparable electrolytes and sodium concentration to plasma, is passed. This is the regime that we have experience in using, but alternative agents are likely to be equally effective, eg thiazide diuretics promoting distal convoluted tubule sodium loss at the final portion of the nephron where 'fine tuning' occurs (eg chlorthalidone or bendroflumethiazide or the quinazoline, metolazone). As a class, these agents prevent maximal urinary dilution (in contrast to furosemide preventing maximal concentration) at the cortical diluting portion of the distal convoluted tubule, in contrast to loop diuretic antagonism of urinary concentration. This different mode of action between thiazides and loop diuretics has clinical implications and accounts for the higher rates of hyponatraemia seen in patients taking the former drugs chronically.
Unanswered questions using this revised 'natriuretic' regime
Can the natriuresis regime adversely affect the kidneys?
The process of tubulo-glomerular feedback has been reviewed elsewhere and is hypothesised to constitute an adenosine- Figure 2 The normal functions of the nephron and interaction with the multiple agent natriuretic regime described. [16] [17] [18] [19] To maintain a consistent GFR, elevated tubular [Na + ] concentration, interpreted as 'excess' GFR, results in afferent arteriolar vasoconstriction and efferent vasodilatation and thus reduced GFR, and vice versa. The induction of pharmacological natriuresis may be hypothesised to reduce the GFR by afferent vasoconstriction. The clinical impact of such a change is unclear and in our patient appeared to be of little consequence, but the possibility of detrimental effects on renal perfusion and oxygen consumption cannot be excluded. Intriguingly a prominent mediator in tubule-glomerular feedback, renal adenosine, may be antagonised by aminophylline and some workers have suggested furosemide may exert this effect, 20 particularly if distal tubular function becomes impaired. However, given the series nature of the renal vasculature, it is equally feasible that afferent vasoconstriction and efferent vasodilatation could increase tubular perfusion pressure and ameliorate tubular ischaemia. The impact of furosemide itself on renal function and recovery, including in the setting of acute kidney injury, remains highly controversial, with clinician equipoise existing for most indications. 21, 22 The high volume of urine passed mandates frequent clinical and biochemical monitoring (every six hours).
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Does it still work and is it safe in the presence of renal impairment?
The patients presented had essentially normal renal function; we are cautious in patients with renal dysfunction because it is theoretically possible to worsen renal function or achieve an unexpected biochemical response. In patients with pre-existing renal impairment, polyuria is difficult to achieve. Collection of parameters of renal function would be a key secondary outcome of any efficacy research (see below).
Does it improve outcomes in ARDS/ALI?
This question cannot be currently answered. However this topic is of acute interest following the initial positive results of the FACCT study, ie negative balance improving outcomes in ARDS. 2 The diuretic regimen used in FACCT was sole-agent furosemide so an appropriate head-to-head evaluation with an optimised 'natriuretic' regimen would be timely.
Would alternative regimes be safe and effective?
The agents described were used because of our experience with them and their ready availability on the hospital formulary. It is highly likely that certain substitutions, eg amiloride for spironolactone or a different combination, eg furosemide and a thiazide, would produce comparable effects. It is certainly a disincentive to use four agents where perhaps two would work as well. Safety issues are also a concern, as trainees fail to follow the rationale for certain drugs (eg aminophylline is perceived to be a bronchodilator and it is discontinued).
Summary
Having been largely disappointed with the results of sole agent diuresis with furosemide (namely dehydration, with little effect on TB Na + ), it is now our practice to use the combination of agents listed in Table 3 to induce natriuresis. On consecutive days, fluid can be removed with little effect on plasma electrolytes and without generating alkalosis. Furthermore, paired urine samples demonstrate hypertonic urine with natriuresis and composition extremely close to that of plasma. We propose that this regimen and the attached physiology is a more rational method to produce negative fluid balance through natriuresis in ARDS. More work is needed to define the optimal agents to produce natriuresis and further studies to demonstrate benefit or otherwise of the proposed regime.
Original articles
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Furosemide Variable infusion Loop diuretic; establishes polyuria through Target 400 mL/h maximum urine output 10-50 mg/h antagonising the medullary concentrating Plasma electrolytes measured every six hours gradient. May act as a pulmonary vasodilator
Aminophylline
Fixed infusion 10 mg/h At this low dose aminophylline is associated Combined furosemide and aminophylline is with natriuresis, possibly via antagonism common in Australasian and European of adenosine [23] [24] [25] practice with relatively little published Acetazolamide Bolus 500 mg 12 hrly A carbonic anhydrase inhibitor acting principally Acetazolamide is unlikely to have an effect if pH >7.45 at the proximal convoluted tubule promoting if the urine is already maximally natriuresis in association with bicarbonaturia, alkalinised (pH 8.0-8.5) antagonising the development of alkalosis 26 Spironolactone 100 mg NG 12 hourly A pro-drug yielding canrenoic acid as a metabolite Canrenoic acid may be administered acts as an aldosterone antagoinist. Acting via DCT parenterally but is not licensed or to ensure potassium retention, bicabonaturia and manufactured in the UK. The pyrazine associated natriuresis derivative amiloride may also be a suitable alternative Table 3 The regime used in achieving a negative fluid balance in ARDS.
